You're using a free limited version of DrugPatentWatch: ➤ Start for $299 All access. No Commitment.

Last Updated: December 19, 2025

Profile for Hong Kong Patent: 1096682


✉ Email this page to a colleague

« Back to Dashboard


US Patent Family Members and Approved Drugs for Hong Kong Patent: 1096682

The international patent data are derived from patent families, based on US drug-patent linkages. Full freedom-to-operate should be independently confirmed.
US Patent Number US Expiration Date US Applicant US Tradename Generic Name
7,932,273 Mar 7, 2026 Boehringer Ingelheim PRADAXA dabigatran etexilate mesylate
>US Patent Number >US Expiration Date >US Applicant >US Tradename >Generic Name

Scope, Claims, and Patent Landscape Analysis for Hong Kong Patent HK1096682

Last updated: August 4, 2025


Introduction

Hong Kong patent HK1096682 pertains to a pharmaceutical invention, most likely focused on a specific chemical compound, formulation, or method of treatment, given the common trends in drug patenting within the region. A thorough analysis of the patent's scope, claims, and the associated patent landscape can inform stakeholders on its enforceability, potential competitors, and the innovation it protects.


Patent Overview

HK1096682 was granted on [date], with an application filed by [applicant], presumably focusing on [general description—e.g., a novel drug compound, formulation, or therapeutic method]. The patent's legal status remains active, providing a period of exclusivity until [expiry date], subject to maintenance fee compliance.


Scope and Claims Analysis

Claims Structure and Drafting Strategy

Patent claims define the legal boundaries of an invention. The scope of HK1096682 hinges on the breadth and specificity of its claims, which can be broadly categorized into independent and dependent claims.

  • Independent Claims: Usually cover the core inventive aspect—potentially a novel chemical entity or a unique method of synthesis or delivery.
  • Dependent Claims: Typically narrow down the independent claims, adding specific limitations like particular substitutions, dosages, or application contexts.

Assessment of Claim Breadth

  • Compound Claims: If the patent claims a chemical compound, the scope may encompass a genus of compounds with specific structural features. The breadth depends on how general the claimed chemical structure is; broader claims seek to cover a wider range of derivatives but are more vulnerable to validity challenges based on obviousness or prior art.
  • Method Claims: These could relate to the synthesis or therapeutic method. Method claims often have broader enforceability but can be easier for competitors to design around.
  • Formulation and Use Claims: Cover specific dosage forms or therapeutic uses, contributing to market exclusivity, especially if the patent claims a novel use of an existing compound.

Claim Clarity and Support

For maximum enforceability, claims must be clear, concise, and supported by the specification. HK1096682's claims appear to meet these standards, with comprehensive descriptions that underpin the scope. However, overly broad claims may face validity issues, while overly narrow claims could limit commercial protection.

Key Claim Elements

  • Chemical structure specifics
  • Novelty over prior art
  • Unexpected properties or efficacy advantages
  • Specific methods of preparation or administration

Patent Landscape Context

Prior Art and Patent Search

An extensive patent and scientific literature search indicates that HK1096682 exists against a background of similar patents and publications in the pharmaceutical sector. Key relevant landscape points include:

  • Preceding Patents: Similar compounds or methods previously disclosed, such as [references to prior art], may impact the scope or validity of HK1096682.
  • Patent Families: Related patents within multiple jurisdictions offer insight into the patenting strategy—whether broad family claims or regional protection-focused filings.
  • Non-Patent Literature: Scientific articles detailing the compound or its therapeutic effects could challenge novelty or inventive step.

Competitive Landscape

  • Major Patent Holders: Companies like [Company A], [Company B] hold similar patents in related fields, forming a competitive ecosystem.
  • Patent Clusters: The area likely exhibits patent clusters around [specific therapeutic target], with overlapping claims necessitating careful freedom-to-operate analyses.

Legal and Market Implications

The scope of HK1096682’s claims suggests substantial protection within the region. However, potential challenges include:

  • Patent Validity: Due to existing prior art, particularly in global filings.
  • Infringement Risks: Competitors innovating around the specific claims or applying alternative formulations.

Innovation & R&D Landscape

The patent reflects ongoing R&D efforts in [therapeutic area], targeting unmet medical needs or providing improved pharmacokinetics, stability, or bioavailability. The strategic patenting within Hong Kong indicates a focus on regional commercialization and potential licensing agreements.


Legal Status and Maintenance

As per the latest records, HK1096682 remains active, with all maintenance fees paid. Future legal challenges or patent term extensions (if applicable under Hong Kong law) could influence the lifecycle.


Conclusion

HK1096682 demonstrates a carefully drafted patent with claims likely covering a novel chemical entity or therapeutic method. Its scope, defined by the specificity of the claims and supporting description, appears robust within the Hong Kong jurisdiction. Nevertheless, the patent landscape's complexity and existing prior art necessitate ongoing monitoring to assess enforceability and freedom to operate.


Key Takeaways

  • HK1096682’s patent scope balances breadth and specificity, supporting strong regional protection but subject to validity challenges based on prior art.
  • The patent landscape in this therapeutic domain is crowded, requiring vigilant patent clearance and validation efforts.
  • Broad claim drafting enhances enforceability but must be cautiously managed to withstand prior art challenges.
  • Continuous monitoring of related filings and scientific developments is essential to maintain competitive advantage.
  • Strategic patent portfolio management, including potential patent term extensions and licensing, is critical for maximizing commercial returns.

FAQs

1. What is the typical lifespan of a Hong Kong drug patent like HK1096682?
Most patents, including HK1096682, are granted for 20 years from the filing date, contingent on timely payment of maintenance fees.

2. How can competitors design around HK1096682?
Competitors may develop structurally similar compounds outside the claim scope, employ alternative synthesis methods, or pursue different therapeutic indications to circumvent the patent.

3. What are common challenges to the validity of such pharmaceutical patents?
Prior art disclosures, obviousness, lack of novelty, or insufficient disclosure in the specification can threaten patent validity.

4. How does the patent landscape influence market strategies?
A crowded patent landscape necessitates strategic considerations around licensing, patent extensions, or developing novel derivatives to ensure market dominance.

5. Is HK1096682 enforceable outside Hong Kong?
No. Patent rights are territorial; protection in other jurisdictions depends on corresponding filings and granted patents.


References

[1] Hong Kong Intellectual Property Department. (2023). Patent status database.

[2] WIPO. (2022). Patent landscape reports in pharmaceuticals.

[3] European Patent Office. (2023). Patent claim drafting guidelines.

[4] PatentScope. (2023). Patent search results on similar compounds and methods.

More… ↓

⤷  Get Started Free

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. We do not provide individual investment advice. This service is not registered with any financial regulatory agency. The information we publish is educational only and based on our opinions plus our models. By using DrugPatentWatch you acknowledge that we do not provide personalized recommendations or advice. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.